Literature DB >> 14764683

Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion.

Phillip Wong1, Eric G Pamer.   

Abstract

Transient TCR stimulation induces multiple rounds of CD8 T cell division without further requirement for Ag. The mechanism driving Ag-independent proliferation, however, remains unclear. In this study, we show that the initial duration of TCR stimulation positively correlates with the number of divisions that CD8 T cells subsequently undergo. We find that increased periods of Ag stimulation result in enhanced CD25 up-regulation and greater IL-2 production by CD8 T cells. Depletion of IL-2 from T cell cultures with specific Abs dramatically impairs programmed proliferation. Consistent with this result, IL-2-deficient T cells undergo markedly attenuated Ag-independent proliferation in vitro. Although IL-2 production by stimulated CD8 T cells appears to be essential for in vitro proliferation, upon transfer into recipient mice, IL-2-deficient CD8 T cells undergo extensive proliferation in vivo after transient stimulation. Furthermore, the extent of in vivo proliferation correlates with the duration of in vitro Ag stimulation. These results indicate that the requirements for autocrine IL-2 production by CD8 T cells differs between in vitro and in vivo conditions and suggests that factors in addition to IL-2 can support Ag-independent CD8 T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764683     DOI: 10.4049/jimmunol.172.4.2171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Distinct temporal programming of naive CD4+ T cells for cell division versus TCR-dependent death susceptibility by antigen-presenting macrophages.

Authors:  Adam G Schrum; Ed Palmer; Laurence A Turka
Journal:  Eur J Immunol       Date:  2005-02       Impact factor: 5.532

3.  A simple immune system simulation reveals optimal movement and cell density parameters for successful target clearance.

Authors:  David Nicholson; Lindsay B Nicholson
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

4.  CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production.

Authors:  Victor Peperzak; Yanling Xiao; Elise A M Veraar; Jannie Borst
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

5.  IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection.

Authors:  Jodi McGill; Nico Van Rooijen; Kevin L Legge
Journal:  J Exp Med       Date:  2010-03-08       Impact factor: 14.307

6.  Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells.

Authors:  Hans-Peter Raué; Carol Beadling; Jennifer Haun; Mark K Slifka
Journal:  Immunity       Date:  2012-12-20       Impact factor: 31.745

7.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

8.  Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response.

Authors:  Reinhard Obst; Hisse-Martien van Santen; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307

9.  Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs.

Authors:  Jodi McGill; Nico Van Rooijen; Kevin L Legge
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

Review 10.  The Timing of T Cell Priming and Cycling.

Authors:  Reinhard Obst
Journal:  Front Immunol       Date:  2015-11-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.